The mid-sized Japanese pharmaceutical firm Kissei is expanding its interests in biosimilars through a new collaboration with the South Korean venture Alteogen.

The major Japanese generics firm Nichi-Iko Pharmaceutical is planning to raise an estimated JPY12.58bn ($123m) in total net proceeds from a new rights offering, with the new funds already earmarked for an array of capital investment and product development projects.

Nichi-Iko Pharmaceutical is continuing its strategic expansion into Southeast Asian markets through a new alliance with Vietnam's Hanoi Pharmaceutical.

Nichi-Iko Pharmaceutical, one of Japan's largest generics firms, has acquired a 12.6% equity stake in Binex, a South Korean contract manufacturer, in an alliance it says will focus on the production of biosimilars.